Duracinsky M, Herrmann S, Berzins B, et al. The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV/AIDS. J Acquir Immune Defic Syndr. 2012;59(5):498-505. https://doi.org/10.1097/QAI.0b013e318245cafe PMID:22205438 DOI: https://doi.org/10.1097/QAI.0b013e318245cafe

Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335-343. https://doi.org/10.1097/QAD.0b013e32834dcec9 PMID:22089374 DOI: https://doi.org/10.1097/QAD.0b013e32834dcec9

Havlir DV, Kendall MA, Ive P, et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-1491. https://doi.org/10.1056/NEJMoa1013607 PMID:22010914 DOI: https://doi.org/10.1056/NEJMoa1013607

Lee SA, Sinclair E, Hatano H, et al. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One. 2014;9(2):e89444. https://doi.org/10.1371/journal.pone.0089444 PMID:24586783 DOI: https://doi.org/10.1371/journal.pone.0089444

Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs. 2018;78(17):1817-1828. https://doi.org/10.1007/s40265-018-1010-7 PMID:30460547 DOI: https://doi.org/10.1007/s40265-018-1010-7

EMA. Riassunto delle Caratteristiche Tecniche del prodotto. Online https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_it.pdf (Accessed September 2024)

Wohl D, Clarke A, Maggiolo F, et al. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018;11(5):561-573. https://doi.org/10.1007/s40271-018-0322-8 PMID:29956087 DOI: https://doi.org/10.1007/s40271-018-0322-8

Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063-2072. https://doi.org/10.1016/S0140-6736(17)32299-7 PMID:28867497 DOI: https://doi.org/10.1016/S0140-6736(17)32299-7

Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357-e365. https://doi.org/10.1016/S2352-3018(18)30092-4 PMID:29925489 DOI: https://doi.org/10.1016/S2352-3018(18)30092-4

Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073-2082. https://doi.org/10.1016/S0140-6736(17)32340-1 PMID:28867499 DOI: https://doi.org/10.1016/S0140-6736(17)32340-1

Sax PE, Rockstroh JK, Luetkemeyer AF, et al; GS-US-380–4030 Investigators. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2021;73(2):e485-e493. https://doi.org/10.1093/cid/ciaa988 PMID:32668455 DOI: https://doi.org/10.1093/cid/ciaa988

Butler K, Anderson SJ, Hayward O, et al. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. J Manag Care Spec Pharm. 2021;27(7):891-903. https://doi.org/10.18553/jmcp.2021.27.7.891 PMID:34185564 DOI: https://doi.org/10.18553/jmcp.2021.27.7.891

Estrada V, Górgolas M, Peña JA, et al. Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain. PharmacoEconom Open. 2022;6(3):415-424. https://doi.org/10.1007/s41669-022-00322-w PMID:35124787 DOI: https://doi.org/10.1007/s41669-022-00322-w

Gill MJ, Powell M, Vu Q, Krentz HB. Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings. HIV Med. 2021;22(8):723-731. https://doi.org/10.1111/hiv.13121 PMID:33979022 DOI: https://doi.org/10.1111/hiv.13121

Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health. 2007;10(5):336-347. https://doi.org/10.1111/j.1524-4733.2007.00187.x PMID:17888098 DOI: https://doi.org/10.1111/j.1524-4733.2007.00187.x

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Online https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (Accessed September 2024)

Lombardia R. Direzione Generale Welfare. Percorso diagnostico terapeutico assistenziale (PDTA) del paziente affetto da infezione/malattia HIV/AIDS. Anno 2021. Online https://www.simit.org/images/regioni/lombardia/comunicazioni/Documenti%20Regionali/PDTA%20HIV%20Regione%20Lombardia%202021.pdf (Accessed September 2024)

Shang Z. Use of Delphi in health sciences research: A narrative review. Medicine (Baltimore). 2023 Feb 17;102(7):e32829. doi: 10.1097/MD.0000000000032829 PMID: 36800594 DOI: https://doi.org/10.1097/MD.0000000000032829

D’Achille A. An analysis of healthcare processes through an Activity-based Costing approach.

Economia Aziendale Online, 2019; S 10(1):93-10. http://dx.doi.org/10.13132/2038-5498/10.1.1948

UNAIDS. End Inequalities. End Aids. Global Aids Strategy 2021-2026. 2021. Online https://www.unaids.org/sites/default/files/media_asset/global-AIDS-strategy-2021-2026_en.pdf (Accessed September 2024)

Garagiola E, Foglia E, Ferrario L, et al. HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting. Int J Environ Res Public Health. 2020;17(23):9010. https://doi.org/10.3390/ijerph17239010 PMID:33287274 DOI: https://doi.org/10.3390/ijerph17239010

Spiegelhalter DJ, Myles JP, Abrams KR. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. 2003. https://doi.org/10.1002/0470092602 DOI: https://doi.org/10.1002/0470092602

Galli M, Borderi M, Viale P. HIV policy in Italy and recommendations across the HIV care continuum. Le Infezioni in Medicina, n. 1, 17-28, 2020 PMID: 32172257

Croce D, Lazzarin A, Rizzardini G, et al. HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy. PLoS One. 2016;11(12):e0168399. https://doi.org/10.1371/journal.pone.0168399 PMID:28030621 DOI: https://doi.org/10.1371/journal.pone.0168399

ISTAT. Indicatori demografici anno 2022. Online https://www.istat.it/it/files/2023/04/indicatori-anno-2022.pdf (Accessed September 2024)

Guinan K, Mathurin K, Lachain J. Economic Impact of Rapid Treatment Initiation of HIV with Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Canadian Healthcare Perspective. Value Health. 2023; S26 (6): S184-S185. https://doi.org/10.1016/j.jval.2023.03.994 DOI: https://doi.org/10.1016/j.jval.2023.03.994

Kolakowska A, Maresca AF, Collins IJ, Cailhol J. Update on Adverse Effects of HIV Integrase Inhibitors. Curr Treat Options Infect Dis. 2019;11(4):372-387. https://doi.org/10.1007/s40506-019-00203-7 PMID:33380904 DOI: https://doi.org/10.1007/s40506-019-00203-7